Steris plc, IE00BFY8C754

Steris plc stock trades 0.40 percent above its prior close

Published on 10/02/2026 at 13:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

STERIS grew first-quarter fiscal 2027 revenue 7.30 percent to USD 1.49 billion. Steris plc stock costs EUR 186.95 on October 2, 2026 after EUR 186.20.

Makroaufnahme glänzender chirurgischer Edelstahlinstrumente mit feinen Sterilisations-Wassertropfen
Steris plc IE00BFY8C754 zeigt in einer Makroaufnahme glänzende chirurgische Edelstahlinstrumente mit feinen Wassertropfen, Illustration mit AI erstellt.

Steris plc (ISIN IE00BFY8C754) was trading at EUR 186.95 at Lang & Schwarz on October 2, 2026 at 1:33 p.m. CEST, plus 0.40 percent versus the prior close of EUR 186.20. The latest operating benchmark is first-quarter fiscal 2027, when adjusted earnings per share rose 10.68 percent year over year to USD 2.59.

First-quarter earnings set the baseline

According to Zacks on September 4, 2026, STERIS reported first-quarter fiscal 2027 adjusted earnings of USD 2.59 per share, up from USD 2.34 in the prior-year quarter. The result exceeded the consensus estimate by 1.97 percent, while GAAP earnings per share reached USD 2.04 versus USD 1.79 a year earlier.

Revenue increased 7.30 percent year over year to USD 1.49 billion but missed the consensus mark by 0.83 percent, according to Zacks. Total backlog advanced 7.70 percent year over year to USD 553.90 million, giving investors a second operating measure beyond the earnings comparison.

Guidance keeps growth in view

STERIS reaffirmed fiscal 2027 as-reported revenue growth guidance of 7.00-8.00 percent and constant-currency organic revenue growth guidance of 6.00-7.00 percent in the Zacks review. Adjusted earnings per share guidance stood at USD 11.10-11.30 for fiscal 2027.

The segment mix adds detail to that outlook. Healthcare revenue rose 7.60 percent to USD 1.05 billion in the first quarter, Applied Sterilization Technologies revenue increased 5.80 percent to USD 297.60 million, and Life Sciences revenue climbed 8.60 percent to USD 146.70 million, according to Zacks.

Analyst targets remain above the US quote

As MarketBeat reported on September 29, 2026, Piper Sandler kept an overweight rating and raised its target from USD 270.00 to USD 275.00 on August 7, while UBS lowered its target from USD 275.00 to USD 270.00 and retained a buy rating on the same date. MarketBeat listed a Moderate Buy consensus and an average target of USD 271.33.

Dividend income also moved higher. MarketBeat reported that STERIS increased its quarterly dividend from USD 0.63 to USD 0.69 per share, a 9.52 percent increase, with the payment made on September 25, 2026.

Euro quote stays below US range

STERIS had a market capitalization of USD 20.4 billion as of October 1, 2026. Its US 52-week range was USD 195.14 to USD 269.44 on the same market-data snapshot, while the Lang & Schwarz quote provides the euro reference for German investors.

The further course of trading is shown by the continuously updated real-time quote of Steris plc stock.

Steris plc stock facts

  • Company: STERIS plc
  • ISIN: IE00BFY8C754
  • Ticker: STE
  • Primary exchange: NYSE
  • Price Lang & Schwarz as of October 2, 2026, 1:33 p.m. CEST: EUR 186.95
  • Change versus prior close: plus 0.40 percent
  • Prior close Lang & Schwarz (October 1, 2026): EUR 186.20
  • Market capitalization: USD 20.4 billion (as of October 1, 2026)
  • 52-week range: USD 195.14-269.44 (as of October 1, 2026)
  • Sector / Industry: Healthcare / Medical Devices

More news and analyses on Steris plc stock

Disclaimer...

en | IE00BFY8C754 | STERIS PLC | boerse | 70215226 | bgmi